{"article_id": "COO_q1_2022.txt", "article": ["regarding first quarter financial results , consolidated revenues were $ 787 million , with coopervision at $ 561 million , up 11 % , and coopersurgical reaching a new all - time high of $ 226 million , up 30 % .", "non-gaap earnings per share were $ 3.24 .", "our coopervision growth of 14 % was strong and diversified .", "we grew nicely in all product categories , spheres , torics and multifocals , and all three regions posted great results , with the americas up 8 % , emea up 17 % and asia pac up 19 % .", "regarding products , our daily silicone hydrogel lenses , myday , and clariti , posted strong results , growing 25 % .", "for our frps , we reported another solid quarter of 10 % growth for avaira and biofinity , our silicone hydrogel two - week and monthly lenses .", "we posted revenues of $ 20 million .", "and within this , misight grew 172 % .", "our team in china is strong , and our advisory board of key opinion leaders that are affiliated with hospitals representing over 50 % of myopia management contact lens volume in china has us positioned for success in a market where childhood myopia rates are estimated to be over 80 % , and we 're reducing myopia as a priority for the government .", "it cuts myopia progression by roughly 59 % on average .", "to conclude on myopia management , our momentum is strong , and we 're still targeting roughly $ 100 million in sales for this fiscal year .", "to wrap up on coopervision , for calendar q4 , we estimate the global contact lens market grew 10 % , with coopervision growing 16 % .", "this demand is great , but it 's still impacting fit activities such as in the u.s. where new fits are still roughly 8 % below pre-covid levels .", "meanwhile , long - term macro growth trends remain intact with roughly one - third of the world being myopic today and that 's expected to increase to 50 % by 2050 .", "in the meantime , we had another strong quarter with organic growth of 9 % .", "we recognized roughly $ 34 million of revenues in the quarter as this was a stub period with only roughly one and a half months of revenue .", "of this , $ 23 million was in stem cell storage and $ 11 million in fertility .", "it 's tough to get exact growth rates for a stub period , but growth for the business for the full equivalent fiscal quarter was 10 % .", "we posted sales of $ 97 million , up a very healthy 27 % when excluding generate and the small acquisition of embryo options from last january .", "within our office and surgical unit , we posted sales of $ 129 million , up 24 % as reported , but down 3 % when excluding generate and other acquisitions .", "having said that , we did see growth in many areas such as our laparoscopic surgery closure products , and our acquired businesses grew nicely , especially fetal pillow in our labor and delivery area , which grew 160 % .", "this industry continues to grow nicely , and we estimate our addressable market is approaching $ 2 billion with 5 % to 10 % long - term annual growth .", "it 's estimated that one in eight couples has trouble getting pregnant due to a variety of factors such as increasing maternal age and that more than 100 million individuals worldwide suffer from infertility .", "first quarter consolidated revenues were $ 787 million , up 16 % and up 13 % organically .", "consolidated gross margin decreased year over year by 90 basis points to 66.9 % , driven primarily by currency , but also lower sales of paragard , partially offset by lower manufacturing costs at coopervision .", "operating expenses grew 19 % to 42.3 % of revenues with the addition of generate and higher investment activity .", "consolidated operating margins were 24.6 % , down from 26.9 % last year due to the negative impact of fx and higher investing .", "interest expense was $ 6.6 million on higher average debt , partially offset by lower interest rates .", "the effective tax rate was 13.3 % , higher primarily due to the generate acquisition .", "non-gaap earnings per share was $ 3.24 with roughly 49.9 million average shares outstanding .", "fx negatively impacted us by $ 0.37 in the quarter , which was $ 0.02 worse than we forecasted at the time of our last earnings call .", "free cash flow was solid at $ 109 million , comprised of $ 166 million of operating cash flow , offset by $ 57 million of capex .", "net debt decreased by $ 1.6 billion to $ 3 billion , driven by the acquisition of generate .", "and our adjusted leverage ratio increased to 2.71 times .", "during the quarter , we repurchased roughly 191,200 shares of the company 's common stock for $ 78.5 million at an average purchase price of $ 410.41 per share , that 's $ 410.41 .", "roughly $ 256 million remains authorized for repurchase under our program .", "prior to the russian invasion of ukraine , this would have meant the midpoint for earnings per share would have been roughly $ 14.35 , but currency has moved significantly against us over the past week .", "with this , the new consolidated revenue range is $ 3.261 billion to $ 3.329 billion , up 6.5 % to 8.5 % organically .", "within this , coopervision revenue guidance is $ 2.221 billion to $ 2.264 billion , up 7 % to 9 % organically .", "coopersurgical revenues are expected to be between $ 1.04 billion and $ 1.065 billion , up 35 % to 38 % as reported or 5 % to 7 % organically .", "non-gaap earnings per share is expected to be in the range of $ 13.70 to $ 14.20 .", "we estimate interest expense around $ 42 million , which assumes a 25 - basis - point rate increase , remembering that $ 1 billion of our debt is fixed -- is at fixed rates .", "we estimate the full year tax rate to be around 14 % .", "regarding currency , on a year - over - year basis , the negative fx headwind is now roughly 3.5 % to revenues and roughly 10 % negative impact to eps .", "regarding cook , we announced this acquisition on february 7 for $ 875 million .", "from a financial perspective , this business had roughly $ 158 million in sales in calendar 2021 , and we expect long - term growth in the range of 5 % to 9 % .", "additionally , we expect year one non-gaap earnings per share accretion of roughly $ 0.60 ."], "summary_gold": "q1 non -gaap earnings per share $ 3.24 .<q>q1 revenue rose 16 percent to $ 787.2 million .<q>sees fiscal 2022 non -gaap diluted earnings per share $ 13.70 - $ 14.20 .", "summary_pred": "net debt decreased by $ 1.6 billion to $ 3 billion , driven by the acquisition of generate .<q>free cash flow was solid at $ 109 million , comprised of $ 166 million of operating cash flow , offset by $ 57 million of capex .<q>fx negatively impacted us by $ 0.37 in the quarter , which was $ 0.02 worse than we forecasted at the time of our last earnings call .<q>and our adjusted leverage ratio increased to 2.71 times .<q>non-gaap earnings per share was $ 3.24 with roughly 49.9 million average shares outstanding .<q>regarding products , our daily silicone hydrogel lenses , myday , and clariti , posted strong results , growing 25 % .<q>within our office and surgical unit , we posted sales of $ 129 million , up 24 % as reported , but down 3 % when excluding generate and other acquisitions .<q>having said that , we did see growth in many areas such as our laparoscopic surgery closure products , and our acquired businesses grew nicely , especially fetal pillow in our labor and delivery area , which grew 160 % .<q>we estimate interest expense around $ 42 million , which assumes a 25 - basis - point rate increase , remembering that $ 1 billion of our debt is fixed -- is at fixed rates .<q>this demand is great , but it 's still impacting fit activities such as in the u.s. where new fits are still roughly 8 % below pre-covid levels .<q>for our frps , we reported another solid quarter of 10 % growth for avaira and biofinity , our silicone hydrogel two - week and monthly lenses .<q>meanwhile , long - term macro growth trends remain intact with roughly one - third of the world being myopic today and that 's expected to increase to 50 % by 2050 .<q>our coopervision growth of 14 % was strong and diversified .<q>we grew nicely in all product categories , spheres , torics and multifocals , and all three regions posted great results , with the americas up 8 % , emea up 17 % and asia pac up 19 % .<q>in the meantime , we had another strong quarter with organic growth of 9 % .<q>we posted revenues of $ 20 million .", "len_article": 47, "len_summary_gold": 3, "len_summary_pred": 16, "len_sent_scores": 47}